Main Menu

This technology includes an antibody that enables the identification and isolation of the protein and protein partners of Vangl2 for application by western blotting, immunoprecipitation and immunocytochemistry. Because planar cell polarity signaling disruption leads to direct or indirect pathologies including malformation of the neural tube, mental retardation, disruption of sensory functions (hearing, balance, vision), cancers (polykystic kidneys disease), or cardiac

This technology includes a bacterial strain derived from BL21 (ED3) CodonPlus Competent Cells containing an expression vector for human POLR2C gene for research purposes. The bacterial strain can be used to produce the full-length human RNA polymerase II subunit, RPB3 protein, which can be in turn isolated and purified.

This technology includes a stable cell line (293T2-PGC) which has an intact PGC-1 alpha/ERR-alpha pathway to screen for environmental chemicals. The estrogen-related receptor alpha (ERR-alpha) and proliferator-activated receptor gamma coactivator - 1alpha (PGC-1 alpha) play critical roles in the control of several physiological functions, including the regulation of genes involved in energy homeostasis. However, little is known about the environmental chemicals that could disrupt or modulate this pathway leading to adverse health effects.

This technology includes p300 KO HEK293T cells using crispr/cas9 mediated gene editing technology to be used for various research applications. We showed that p300 deficient cells have impaired glycolysis and are hypersensitive to glucose depletion-induced cell death. p300 is one of major transcriptional co-activators that regulates gene transcription as a histone acetyltransferase. Recent studies reveal that it functions as "writer" for a variety of lysine acylations, including acetylation, crotonylation, butryrylation, 2- hydroxyisobutyrylation, and succinylation.

This technology includes EPHX1/EPHX2 null mice and showed that disruption of both EPHX1 and EPHX2 almost completely abolished hydrolysis of several EETs which can be used in the treatment of cardiovascular diseases. EPHX 1 is significantly involved in EET hydrolysis, and we believe the combined use of EPHX1 and EPHX2 inhibitors would provide a better alternative to currently available therapeutic options or the EPHX2-based therapies currently in trials for the treatment of cardiovascular diseases.

This technology includes identified members of the mouse cytochromes P450 CYP2J subfamily and antibodies to them for P450 expression studies and metabolism research. Recombinant proteins of the CYP2J subfamily members have also been expressed. The CYP2J subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism, and toxicity.

This technology includes a series of recombinase responsive indicator alleles in genetically modified laboratory mice which uniquely permit non-invasive labeling of cells defined by the overlap of up to three distinct gene expression domains. In response to any combination of Cre, Flp and Dre recombinases, these alleles express high levels of eGFP and/or tdTomato that allow the visualization of cells in live and fixed tissue, including samples processed using modern tissue clearing techniques.

This technology includes a paper strip tool that may be used at the point-of care to detect the presence of a multiplex of pathogen nucleic acid sequences in stool without the need for molecular amplification, laboratory or instrumentation. This invention can be used to rapidly and inexpensively detect gastrointestinal and diarrheal disease in order to guide treatment.

This technology includes synthesized demonstrated [1-13C] NAC as a promising novel probe for hyperpolarized 13C MRI methodologies which could provide diagnostic, and evaluation of response to treatment in various cancers and neurological diseases. N-acetyl cysteine (NAC) is a widely used therapeutic and involved to stimulate glutathione synthesis. Glutathione elevates detoxification and works directly as a free radical scavenger. In vivo hyperpolarized NAC was broadly distributed throughout the body.

This technology includes six human monoclonal antibodies (mAbs) that target tumor antigens derived from the CT-RCC HERV-E (human endogenous retrovirus type E) to generate Chimeric Antigen Receptor (CAR) T cells to treat patients with advanced clear cell renal cell carcinoma (ccRCC). These mAbs were identified from Adagene Inc’s human antibody phage library, and data show that majority of these mAbs only bind to CT-RCC HERV-E+ ccRCC cells, which express TM but not CT-RCC HERV-E non-expressing ccRCC cells nor non-RCC cells.